RightFit
RecruitingPhase not listed

Transgene Assay Testing Service of Tumor Samples From Patients Who Received a Bristol-Myers Squibb Manufactured Gene Modified Cell Therapy and Have a Qualifying Second Primary Malignancy

Protocol for Transgene Assay Service

Who can join

As published by the study on ClinicalTrials.gov. "Not stated" means the study hasn't said — ask the study team.

Age
No age limits stated
Sex
All sexes
Healthy volunteers
Not stated
Compensation
Not stated

Other requirements are listed under Eligibility below. Only the study team can confirm whether you can join.

What to expect

No one can promise a trial will help you personally — that is what the research is trying to find out.

What participation involves

Not stated in the study description — ask the study team about visits and procedures.

Compensation
Not stated
  • Study-related exams and procedures are typically provided at no cost. This is how many trials work in general — confirm the details for this study with the study team.
  • Participants are monitored closely by the research team throughout the study.
  • Some participants may receive access to an investigational treatment, which is still being studied.
  • Your participation helps researchers learn whether this approach could help future patients.

About this study

In plain language

This testing service checks tumor samples for levels of a gene added during cell therapy. It is for people who received a Bristol-Myers Squibb (BMS) gene-modified cell therapy and later had a new, separate cancer that qualifies for testing.

The purpose of this transgene assay testing service is to evaluate tumor samples for transgene levels in patients who received a commercially available Bristol-Myers Squibb manufactured gene modified cellular therapy and have reported a qualifying second malignancy.

Compensation is read from the study's own description and may be missing — always confirm with the study team.

Eligibility

Who can join

  • You received a BMS gene-modified cell therapy—a treatment using cells with changed genes—that is available for sale, and you have a new, separate cancer that qualifies for testing.
  • You may also qualify if you received this therapy in a clinical trial or other research setting, including a product that did not meet all product standards. That setting must have no testing plan in place, and your new, separate cancer must qualify for testing.

Who can't join

  • You are currently in a clinical trial that is collecting your information and samples.
  • You have not received a BMS gene-modified cell therapy, or you do not have a new, separate cancer that qualifies for testing.

Simplified for readability. The official criteria below are what the study team uses.

Official eligibility criteria

Inclusion Criteria: * Participant has received a commercially available Bristol-Myers Squibb (BMS) manufactured Gene Modified Cell Therapy (GMCT) and has been diagnosed with a qualifying second primary malignancy or a second primary malignancy which BMS has qualified for testing. * Participant has received a commercially available BMS manufactured GMCT in a clinical trial or other investigational setting (including non-conforming product) for which there is no testing protocol in place for that trial or investigational setting and has been diagnosed with a qualifying second primary malignancy or a second primary malignancy which BMS has qualified for testing. Exclusion Criteria: * Participant is actively participating in a clinical trial where information and sample collection is being conducted under that clinical trial. * Participant has not received a BMS manufactured GMCT or has not been diagnosed with a qualifying second primary malignancy.

Study sites (4)

OR

TX

UT

  • Huntsman Cancer Institute at the University of Utah · Salt Lake City, UT 84112Lauren Lee, Site 0010 · Study contactMore trials in Salt Lake City

WI